Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CDC25B | P30305 | 2/20 | 0.55 |
| ▸ | S100A4 | P26447 | 3/20 | 0.52 |
| ▸ | TDP2 | O95551 | 3/20 | 0.52 |
| ▸ | PTPRC | P08575 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | MAOA | P21397 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | APAF1 | O14727 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.52 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167625 | 0.98 | MEN1 (0.57) | MEN1KMT2ACDC25BS100A4TDP2 | |
| SCHEMBL1929100 | 0.95 | MEN1 (0.55) | MEN1KMT2ACDC25BS100A4TDP2 | |
| SCHEMBL9799712 | 0.91 | MEN1 (0.36) | MEN1KMT2ACDC25BS100A4TDP2 | |
| SCHEMBL7148476 | 0.91 | MEN1 (0.43) | MEN1KMT2ACDC25BS100A4TDP2 | |
| SCHEMBL20774014 | 0.83 | MEN1 (0.36) | MEN1KMT2ACDC25BS100A4TDP2 | |
| SCHEMBL1350657 | 0.83 | MEN1 (0.36) | MEN1KMT2ACDC25BS100A4TDP2 | |
| Water SCHEMBL7789828 | 0.80 | MEN1 (0.86) | MEN1KMT2ACDC25BS100A4TDP2 | |
| SCHEMBL8659735 | 0.78 | ADORA2A (0.41) | MEN1KMT2ACDC25BMAPK1MAOA | |
| SCHEMBL31884 | 0.77 | MEN1 (0.92) | MEN1KMT2ACDC25BS100A4TDP2 | |
| Anthraquinone SCHEMBL6415478 | 0.77 | MEN1 (0.92) | MEN1KMT2ACDC25BS100A4TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021078217-A1 | TETRACENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 中国科学院化学研究所 | 2021-04-29 | — | — | WO | claimed |
| CN-112694388-A | Naphthacene derivative and preparation method and application thereof | 中国科学院化学研究所 | 2021-04-23 | — | — | CN | claimed |
| EP-2421852-B9 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | claimed |
| EP-2421823-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-14 | — | — | EP | claimed |
| CN-102548983-B | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2014-09-17 | — | — | CN | claimed |
| US-8815839-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-26 | — | — | US | claimed |
| EP-2421852-B1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | claimed |
| US-8492398-B2 | Spiroazaindoles | MERCK SHARP & DOHME CORP. (US) | 2013-07-23 | — | — | US | claimed |
| US-20130184251-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-07-18 | — | — | US | claimed |
| EP-2160187-B1 | SPIROINDALONES | MERCK SHARP & DOHME (US) | 2013-05-22 | — | — | EP | claimed |
| WO-2003059905-A1 | PYRROLIDONE CARBOXAMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-07-24 | — | — | WO | claimed |
| US-6479505-B1 | TREATING AIRWAY DISORDER IN A PATIENT COMPRISING ADMINISTERING TO SAID PATIENT IN NEED THEREOF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A PHOSPHODIESTERASE IV INHIBITOR | ALTANA PHARMA AG (DE) | 2002-11-12 | — | — | US | claimed |
| EP-1193250-A1 | PHENYL SULFAMATE DERIVATIVES | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2002-04-03 | — | — | EP | claimed |
| EP-1147088-A1 | 6-ARYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-10-24 | — | — | EP | claimed |
| EP-1144381-A2 | SUBSTITUTED BENZO[DE]ISOQUINOLINE-1,3-DIONES | MERCK PATENT GmbH (DE) | 2001-10-17 | — | — | EP | claimed |
| WO-2000042019-A1 | 6-ARYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-07-20 | — | — | WO | claimed |
| WO-2000032577-A2 | SUBSTITUTED BENZO[DE]ISOQUINOLINE-1,3-DIONES | MERCK PATENT GMBH (DE) | 2000-06-08 | — | — | WO | claimed |
| EP-0929563-A1 | 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | Abbott Laboratories (US) | 1999-07-21 | — | — | EP | claimed |
| US-5866549-A | MACROLIDE ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1999-02-02 | — | — | US | claimed |
| WO-1998009978-A1 | 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | ABBOTT LABORATORIES (US) | 1998-03-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184251-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPC | MEN1 4471/4885KMT2A 780/4885CDC25B 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.